Literature DB >> 20216119

Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes.

Marta Concheiro1, Hendreé E Jones, Rolley E Johnson, Robin Choo, Diaa M Shakleya, Marilyn A Huestis.   

Abstract

Buprenorphine is approved as pharmacotherapy for opioid dependence in nonpregnant patients in multiple countries and is currently under investigation for pregnant women in the United States and Europe. This research evaluates the disposition of buprenorphine, opiates, cocaine, and metabolites in five term placentas from a US cohort. Placenta and matched meconium concentrations were compared, and relationships among maternal buprenorphine dose, placenta concentrations, and neonatal outcomes after controlled administration during gestation were investigated. Buprenorphine and/or metabolites were detected in all placenta specimens and were uniformly distributed across this tissue (coefficient of variation less than 27.5%, four locations), except for buprenorphine in three placentas. In two of these, buprenorphine was not detected in some locations and in the third placenta was totally absent. Median (range) concentrations were 1.6 ng/g buprenorphine (not detected to 3.2), 14.9 ng/g norbuprenorphine (6.2-24.2), 3 ng/g buprenorphine-glucuronide (1.3-5.0), and 14.7 ng/g norbuprenorphine-glucuronide (11.4-25.8). Placenta is a potential alternative matrix for detecting in utero buprenorphine exposure, but at lower concentrations (15- to 70-fold) than in meconium. Statistically significant correlations were observed for mean maternal daily dose from enrollment to delivery and placenta buprenorphine-glucuronide concentration and for norbuprenorphine-glucuronide concentrations and time to neonatal abstinence syndrome onset and duration, for norbuprenorphine/norbuprenorphine-glucuronide ratio and maximum neonatal abstinence syndrome score, and newborn length. Analysis of buprenorphine and metabolites in this alternative matrix, an abundant waste product available at the time of delivery, may be valuable for prediction of neonatal outcomes for clinicians treating newborns of buprenorphine-exposed women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216119      PMCID: PMC2921577          DOI: 10.1097/FTD.0b013e3181d0bd68

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  34 in total

1.  Treatment of opioid dependence in pregnant women.

Authors:  G Fischer
Journal:  Addiction       Date:  2000-08       Impact factor: 6.526

Review 2.  Biotransformation of xenobiotics in the fetus.

Authors:  O Pelkonen
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

3.  Fetal morphine metabolism and clearance are constant during late gestation.

Authors:  Marianne Garland; Kirsten M Abildskov; Samantha Taylor; Kenza Benzeroual; Casper S Caspersen; Sylvia E Arroyo; Tung-Wah Kiu; Boris Reznik; Piper Weldy; Salha S Daniel; Raymond I Stark
Journal:  Drug Metab Dispos       Date:  2006-01-27       Impact factor: 3.922

4.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Authors:  Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

5.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

Authors:  D Lacroix; M Sonnier; A Moncion; G Cheron; T Cresteil
Journal:  Eur J Biochem       Date:  1997-07-15

Review 6.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

Authors:  D R Nelson; L Koymans; T Kamataki; J J Stegeman; R Feyereisen; D J Waxman; M R Waterman; O Gotoh; M J Coon; R W Estabrook; I C Gunsalus; D W Nebert
Journal:  Pharmacogenetics       Date:  1996-02

7.  Dynamic balanced randomization for clinical trials.

Authors:  D F Signorini; O Leung; R J Simes; E Beller; V J Gebski; T Callaghan
Journal:  Stat Med       Date:  1993-12-30       Impact factor: 2.373

Review 8.  Treatment of opioid-dependent pregnant women: clinical and research issues.

Authors:  Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer
Journal:  J Subst Abuse Treat       Date:  2008-01-14

9.  Aromatase is the major enzyme metabolizing buprenorphine in human placenta.

Authors:  Sujal V Deshmukh; Tatiana N Nanovskaya; Mahmoud S Ahmed
Journal:  J Pharmacol Exp Ther       Date:  2003-06-13       Impact factor: 4.030

10.  Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers.

Authors:  W Luck; H Nau; R Hansen; R Steldinger
Journal:  Dev Pharmacol Ther       Date:  1985
View more
  18 in total

Review 1.  Objective Testing: Urine and Other Drug Tests.

Authors:  Scott E Hadland; Sharon Levy
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2016-03-30

2.  Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.

Authors:  Marta Concheiro; Hendreé E Jones; Rolley E Johnson; Robin Choo; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

3.  P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.

Authors:  Michael Z Liao; Chunying Gao; Laura M Shireman; Brian Phillips; Linda J Risler; Naveen K Neradugomma; Prachi Choudhari; Bhagwat Prasad; Danny D Shen; Qingcheng Mao
Journal:  Pharmacol Res       Date:  2017-01-19       Impact factor: 7.658

Review 4.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 5.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

6.  Fetal assessment before and after dosing with buprenorphine or methadone.

Authors:  Amy L Salisbury; Mara G Coyle; Kevin E O'Grady; Sarah H Heil; Peter R Martin; Susan M Stine; Karol Kaltenbach; Manfred Weninger; Hendrée E Jones
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

Review 7.  CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening.

Authors:  Tanya Chhibber; Sounak Bagchi; Behnaz Lahooti; Angela Verma; Abraham Al-Ahmad; Manash K Paul; Gurudutt Pendyala; Rahul Dev Jayant
Journal:  Drug Discov Today       Date:  2019-11-26       Impact factor: 7.851

8.  A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report.

Authors:  Daisy J Goodman; Catherine U Milliken; Regan N Theiler; Benjamin R Nordstrom; Sarah C Akerman
Journal:  J Dual Diagn       Date:  2015

9.  Opioids affect the fetal brain: reframing the detoxification debate.

Authors:  Steve N Caritis; Ashok Panigrahy
Journal:  Am J Obstet Gynecol       Date:  2019-07-16       Impact factor: 8.661

10.  Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.

Authors:  Caitlin E Martin; Caroline Shadowen; Bhushan Thakkar; Travis Oakes; Tamas S Gal; F Gerard Moeller
Journal:  Curr Treat Options Psychiatry       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.